Odanacatib for the treatment of osteoporosis

Bibliography

• Papaioannou A, Morin S Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182(17):1864-73
   PubMed Web of Science ®Google Scholar
• Strom O, Borgstrom F, Kanis JA, et al. Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 2011;6(1-2):59-155
   Google Scholar
• Chapurlat RD, Arlot M, Burt-Pichat B, et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. J Bone Miner Res 2007;22(10):1502-9
   Google Scholar
• Stepan JJ, Burr DB, Pavo I, et al. Low bone mineral density is associated with bone microdamage accumulation in postmenopausal women with osteoporosis. Bone 2007;41:378-85
   PubMed Web of Science ®Google Scholar
• Boonen S, Rosenberg E, Claessens F, et al. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep 2012;10(1):73-9
   PubMed Web of Science ®Google Scholar
• Bromme D, Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin Investig Drugs 2009;18(5):585-600
   PubMed Web of Science ®Google Scholar
• Novinec M, Lenarcic B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 2013;394(9):1163-79
   Google Scholar
• Leung P, Pickarski M, Zhuo Y, et al. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Bone 2011;49(4):623-35
   Google Scholar
• Rodan SB, Duong LT. Cathepsin K – A new molecular target for osteoporosis. IBMS BoneKey 2008;5(1):16-24
   Google Scholar
• Everts V, Korper W, Hoeben KA, et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 2006;21(9):1399-408
   PubMed Web of Science ®Google Scholar
• Martin TJ, Sims NA. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 2005;11(2):76-81
   PubMed Web of Science ®Google Scholar
• Lotinun S, Kiviranta R, Matsubara T, et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J Clin Invest 2013;123(2):666-81
   PubMed Web of Science ®Google Scholar
• Gelb BD, Shi GP, Chapman HA, et al. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 1996;273(5279):1236-8
   PubMed Web of Science ®Google Scholar
• Fratzl-Zelman N, Valenta A, Roschger P, et al. Decreased bone turnover and deterioration of bone structure in two cases of pycnodysostosis. J Clin Endocrinol Metab 2004;89(4):1538-47
   Google Scholar
• De Vernejoul MC, Kornak U. Heritable sclerosing bone disorders: presentation and new molecular mechanisms. Ann N Y Acad Sci 2010;1192:369-77
   Google Scholar
• Saftig P, Hunziger E, Wehmeyer O, et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K deficient mice. Proc Natl Acad Sci 1998;95:13453-8
   PubMed Web of Science ®Google Scholar
• Gowen M, Lazner F, Dodds R, et al. Cathepsin, K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 1999;14:1654-63
   PubMed Web of Science ®Google Scholar
• Pennypacker B, Shea M, Liu Q, et al. Bone density, strength, and formation in adult cathepsin K (-/-) mice. Bone 2009;44:199-207
   PubMed Web of Science ®Google Scholar
• Kiviranta R, Morko J, Uusitalo H, et al. Accelerated turnover of metaphyseal trabecular bone in mice overexpressing cathepsin K. J Bone Miner Res 2001;16:1444-52
   PubMed Web of Science ®Google Scholar
• Masarachia PJ, Pennypacker BL, Pickarski M, et al. Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys. J Bone Miner Res 2012;27(3):509-23
   PubMed Web of Science ®Google Scholar
• Cusick T, Chen CM, Pennypacker BL, et al. Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey. J Bone Miner Res 2012;27(3):524-37
   PubMed Web of Science ®Google Scholar
• Fratzl-Zelman N, Roschger P, Fisher JE, et al. Effects of Odanacatib on bone mineralization density distribution in thoracic spine and femora of ovariectomized adult rhesus monkeys: a quantitative backscattered electron imaging study. Calcif Tissue Int 2013;92(3):261-9
   Google Scholar
• Williams DS, McCracken PJ, Purcell M, et al. Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate. Bone 2013;56(2):489-96
   PubMed Web of Science ®Google Scholar
• Cabal A, Jayakar RY, Sardesai S, et al. High-resolution peripheral quantitative computed tomography and finite element analysis of bone strength at the distal radius in ovariectomized adult rhesus monkey demonstrate efficacy of odanacatib and differentiation from alendronate. Bone 2013;56(2):497-505
   Google Scholar
• Pennypacker BL, Duong le T, Cusick TE, et al. Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits. J Bone Miner Res 2011;26(2):252-62
   PubMed Web of Science ®Google Scholar
• Stoch SA, Zajic S, Stone JA, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009;86(2):175-82
   PubMed Web of Science ®Google Scholar
• Stoch SA, Zajic S, Stone JA, et al. Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies in healthy volunteers. Br J Clin Pharmacol 2013;75(5):1240-54
   Google Scholar
• Bone HG, McClung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25(5):937-47
   PubMed Web of Science ®Google Scholar
• Eisman JA, Bone HG, Hosking DJ, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J Bone Miner Res 2011;26(2):242-51
   PubMed Web of Science ®Google Scholar
• Langdahl B, Binkley N, Bone H, et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study. J Bone Miner Res 2012;27(11):2251-8
   PubMed Web of Science ®Google Scholar
• Nakamura T, Shiraki M, Fukunaga M, et al. Effect of the cathepsin K inhibitor odanacatib administered once weekly on bone mineral density in Japanese patients with osteoporosis–a double-blind, randomized, dose-finding study. Osteoporos Int 2014;25(1):367-76
   Google Scholar
• Bonnick S, De Villiers T, Odio A, et al. Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial. J Clin Endocrinol Metab 2013;98(12):4727-35
   PubMed Web of Science ®Google Scholar
• Brixen K, Chapurlat R, Cheung AM, et al. Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial. J Clin Endocrinol Metab 2013;98(2):571-80
   PubMed Web of Science ®Google Scholar
• Jensen AB, Wynne C, Ramirez G, et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin Breast Cancer 2010;10(6):452-8
   Google Scholar
• Gajic-Veljanoski O, Tomlinson G, Srighanthan J, et al. Effect of odanacatib on BMD and fractures: estimates from bayesian univariate and bivariate meta-analyses. J Clin Endocrinol Metab 2014;99(9):3070-9
   Google Scholar
• Cheung AM, Majumdar S, Brixen K, et al. Effects of odanacatib on the radius and tibia of postmenopausal women: improvements in bone geometry, microarchitecture, and estimated bone strength. J Bone Miner Res 2014;29(8):1786-94
   PubMed Web of Science ®Google Scholar
• Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int 2015;26(2):699-712
   Web of Science ®Google Scholar
• A study of MK-0822 in postmenopausal women with osteoporosis to assess fracture risk (MK-0822-018). Merck Co, Inc. 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00529373?term_NCT00529373&rank_1 [Last accessed 23 March 2015]
   Google Scholar
• Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, and Investigational Oral, Once-weekly Treatment for osteoporosis. Merck Co, Inc. 2014. Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st [Last accessed 23 March 2015]
   Google Scholar
• Recker R, Dempster D, de Villiers T, et al. Effects of Odanacatib on bone structure and quality in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT). J Bone Miner Res 2014;29(Suppl 1). Available from: http://www.asbmr.org/education/2014-abstracts [Last accessed 8 October 2014]
   Google Scholar
• McClung M, Langdahl B, Papapoulos S, et al. Odanacatib anti-fracture efficacy and safety in postmenopausal women with osteoporosis. Results from the phase III long-term odanacatib fracture trial (LOFT). J Bone Miner Res 2014;29(Suppl 1). Available from: http://www.asbmr.org/education/2014-abstracts [Last accessed 8 October 2014]
   Google Scholar
• Harris S, Watts N, Genant H, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) study group. JAMA 1999;282(14):1344-52
   PubMed Web of Science ®Google Scholar
• Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 1998;280(24):2077-82
   PubMed Web of Science ®Google Scholar
• Cummings SR, San Marin J, McClung M, et al. Denosumab for prevention of fracture in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282(7):637-45
   PubMed Web of Science ®Google Scholar
• Runger TM, Adami S, Benhamou CL, et al. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2012;66(3):e89-96
   PubMed Web of Science ®Google Scholar
• Peroni A, Zini A, Braga V, et al. Drug induced morphea: report of a case induced by balicatib and review of the literature. J Am Acad Dermatol 2008;59(1):125-9
   Google Scholar
• Buhling F, Rocken C, Brasch F, et al. Pivotal role of cathepsin K in lung fibrosis. Am J Pathol 2004;164:2203-16
   PubMed Web of Science ®Google Scholar
• Ng K. Potential role of odanacatib in the treatment of osteoporosis. Clin Intern Ageing 2012;7:2235-47
   Google Scholar
• Papapoulos S, McClung M, Langdahl B, et al. Safety and tolerability of odanacatib therapy in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT). J Bone Miner Res 2014;29(Suppl 1). Available from: http://www.asbmr.org/education/2014-abstracts [Last accessed 8 October 2014]
   Google Scholar
• Dauth S, Sîrbulescu RF, Jordans S, et al. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci 2011;27(12):74
   Google Scholar
• Aoki T, Kataoka H, Ishibashi R, et al. Cathepsin B, K, and S are expressed in cerebral aneurysms and promote the progression of cerebral aneurysms. Stroke 2008;39:2603-10
   PubMed Web of Science ®Google Scholar
• Cheng XW, Huang Z, Kuzuya M, et al. Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications. Hypertension 2011;58(6):978-86
   Google Scholar
• Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012;27(12):2544-50
   PubMed Web of Science ®Google Scholar
• Kassahun K, McIntosh I, Koeplinger K, et al. Disposition and metabolism of the cathepsin K inhibitor odanacatib in humans. Drug Metab Dispos 2014;42(5):818-27
   PubMed Web of Science ®Google Scholar